Shots:

• Akili to receive $20M upfront- $105M as development & commercialization milestones- making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive development & commercialization rights for Akili’s digital medicine- AKL-T01 and AKL-T02 in Japan and Taiwan
• Acc. to an agreement- Shionogi will be responsible for regulatory filings in Japan & Taiwan. Akili has an exclusive global right to develop & commercialize its digital medicines excluding Japan & Taiwan
• Akili’s AKL-T01 and AKL-T02 are a digital treatment for attention-deficit/hyperactivity disorder (ADHD) & Autism Spectrum Disorder (ASD) respectively in children

Ref: Akili | Image: Business Wire